Patent ID: 8591943

Claim:
A method of treating a disease by inhibiting a mTOR, comprising administering to a patient in need of such treatment an amount of a first compound represented by the structural Formula I: or a pharmaceutically acceptable salt, or ester thereof, wherein: R is independently selected from the group consisting of halo, hydroxyl, amino, —CN, H, —(C 1 -C 6 )alkyl, alkoxy, —C(═O)alkyl, heteroaryl and aryl, wherein each of said heteroaryl and aryl can be unsubstituted or substituted with one or more alkyl or halo; R 1 is independently selected from the group consisting of heterocycloalkyl, spiroheterocycloalkyl, heterocyclenyl, —NR 3 R 4 , cycloalkyl, heteroaryl, aryl, alkynyl, heterocyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heteroarylalkynyl, —N-heteroaryl, and arylalkyl, wherein each of said heterocycloalkyl, spiroheterocycloalkyl, heterocyclenyl, cycloalkyl, heteroaryl, aryl, alkynyl, heterocyclenylalkyl, cycloalkylalkyl, heteroarylalkyl, heteroarylalkynyl, —N-heteroaryl and arylalkyl can be unsubstituted or substituted with one or moieties independently selected from the group X; X is alkoxyl, alkyl, —C(O)alkyl, —C(O)-hydroxyalkyl, —C(O) 2 alkyl, —C(O) 2 H, hydroxyalkyl, —S(O) 2 alkyl, hydroxyl, heterocycloalkyl, —NH-heterocycloalkyl, -trihaloalkyl, -dihaloalkyl, -monohaloalkyl, —N—S(O) 2 -alkyl, —C(O)-heteroaryl, -alkyl-C(O) 2 H, -alkyl(CO)N(CH 3 )—O—CH 3 , -alkyl(CO)-heteroaryl, —C(O) 2 -alkyl, -alkyl-C(O)—NH 2 , —NH 2 , heteroaryl, -alkyl-CN, —C(O) 2 -arylalkyl, halo, carboxyesteralkyl, —C(O)—NH 2 , -alkyl-C(O) 2 alkyl, heteroarylalkyl, —C(O)-heteroaryl, —C(O)-alkyl-O-alkyl, -alkyl(CO)NS(O) 2 -cycloalkyl, -alkyl(CO)N—S(O) 2 —CF 3 , —N-alkyl, —SO 2 -cycloalkyl, -alkyl(CO)NS(O) 2 -alkyl, -alkyl-C(O)—N(alkyl) 2 , -alkyl-NS(O) 2 -alkyl, alkyl(CO)NS(O) 2 -cycloalkyl, —CO—CO 2 H, —C(O) 2 -alkyl-aryl, —SO 2 —CF 3 or —C(O)H, wherein each of said heterocycloalkyl, heteroaryl or —C(O)-heteroaryl can be unsubstituted or substituted with one or more alkyl; R 2 is pyridyl optionally substituted with one or more moieties independently selected from the group consisting of alkyl, alkoxyl, —CN, aryloxyl, aryl, halo, hydroxyl, —C(CH 3 ) 2 CN, trifluoromethyl, difluoromethyl, monofluoromethyl, heterocycloalkyl, and arylalkyl; R 3 is cycloalkyl or heteroaryl, wherein each of said cycloalkyl or heteroaryl can be unsubstituted or substituted with one or more moieties independently selected from the group consisting of X; and R 4 is H; and optionally an amount of at least one second compound, said second compound being an anti-cancer agent; wherein the amounts of the first compound and said second compound result in a therapeutic effect.